New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel)...
New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer: CARD is a treatment sequencing trial investigating the efficacy and safety of Jevtana versus abiraterone or enzalutamide after disease progression following initial androgen receptor-targeted agent therapy and docetaxel
About this item
Full title
New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer: CARD is a treatment sequencing trial investigating the efficacy and safety of Jevtana versus abiraterone or enzalutamide after disease progression following initial androgen receptor-targeted agent therapy and docetaxel
Publisher
New York: PR Newswire Association LLC
Journal title
PR Newswire, 2019
Language
English
Formats
Publication information
Publisher
New York: PR Newswire Association LLC
Subjects
More information
Alternative Titles
Full title
New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer: CARD is a treatment sequencing trial investigating the efficacy and safety of Jevtana versus abiraterone or enzalutamide after disease progression follo...
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_2299132282
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_2299132282
How to access this item
Log in as a Library member
